Human Vaccines: A Global Strategic Business Report
San Jose, California (PRWEB) March 13, 2012
Follow us on LinkedIn – Vaccines market is undergoing major changes since the recent years, with globalization being at the forefront of all the changes. Dynamic changes brought about by the globalization include regulatory coordination, increased financial support for low-income countries, provision of intellectual property rights through WTO agreements, and the emergence of vaccine manufacturers of developing countries as major market players. However, one major negative aspect of globalization is the evolution of new contagious diseases, including potential threat from bioterrorism. This has, nevertheless, opened a new avenue for vaccine manufacturers, who are coming out with new vaccines to combat bioterrorism.
Unlike several life science sectors that felt the impact of the global crisis, the human vaccines market remained resilient to the global economic recession. Irked by weakened pipelines and growing pressure from patent expiries, the big pharma majors such as AstraZeneca and Pfizer found vaccines industry a safe avenue to invest and register guaranteed revenues. Regional players from the fast developing vaccine markets, such as India and China, are primarily engaged in meeting demands of public supply for routine and immunization vaccines. Increased demand for more number of pediatric vaccines especially in the developing countries, and surging demand for more number of travel vaccines represents the other growth drivers.
The market outlook for vaccines remains positive, backed by the growing public awareness. Growth would also be dependent on the level of investments in research to determine new technologies. Stronger support from both governmental and non-governmental agencies, such as the WHO and UNICEF, introduction of new vaccines with increased safety and effectiveness, and easy accessability of vaccines to general public are expected to drive the sales of vaccines in the following years. Key growth propellers for the vaccines market revolves around the development of new therapeutic and prophylactic vaccines for combating HIV/AIDS, Congenital Abnormalities, Malaria, SARS and Cancer, apart from other fatal diseases. Further, technological advancements in the molecular genetics domain would be the major factor driving growth of the human vaccines market.
Prophylactic vaccines constitute the largest earners in the Human Vaccines market. Presently, vaccines are available for select diseases, such as Diarrhoea (Rotavirus), Tetanus, ARI (Pneumococcus), Measles, Pertussis, and ARI (Haemophilus influenzae type B), presenting significant unmet medical needs for several other diseases. Prevnar, Gardasil, Infantrix/Pediatrix, Fluzone, and IPOL were few of the best-selling vaccine brands in the recent years. Other vaccine brands witnessing encouraging gains include Rotarix, Cervarix, and RotaTeq. Therapeutic vaccines are expected to spring major surprises in the years ahead. Therapeutic vaccines are projected to grow rapidly over the coming years. Companies are investing a major chunk of research resources in developing therapeutic vaccines, capable of fighting diseases such as cancer, AIDS, and other fatal diseases.
Globally, the major human vaccines markets include North America, Europe, Japan, Australia, and New Zealand. Vaccines demand in these regions is most promising, as large companies have lined up premium range of therapeutic vaccines to be launched in these markets, once regulatory clearances are obtained. The US represents the largest market for prophylactic human vaccines, accounting for more than half of the global market. However, growth is forecast to emanate mostly from the developing regions of Asia-Pacific, Latin America, and Rest of World. Asia-Pacific is projected to register the fastest growth of about 15% over the analysis period.
Global human vaccines market is witnessing fierce competition, with several players foraying into the lucrative vaccine domain. Competition intensified with the entry of several biotech and pharmaceutical companies, which shifted their focus towards vaccines. Key players profiled in the report include GlaxoSmithKline, Sanofi, Merck, Novartis, and Pfizer. Other major companies include ALK – Abelló A/S, Bavarian Nordic A/S, Crucell N.V., CSL Ltd. Medimmune Inc., Vaxin Inc., among others.
The research report titled "Human Vaccines: A Global Strategic Business Report" announced by Global Industry Analysts Inc., provides a comprehensive review of the human vaccines market, current market trends, key growth drivers, prophylactic and therapeutic vaccines pipeline, pipeline projects of major companies, recent industry activity, and profiles of major/niche global market participants. The report provides annual sales estimates and projections for the global Human (Prophylactic) Vaccines market for the years 2009 through 2017 for the regions, including US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World. Key segments analyzed include Adult Prophylactic Vaccines and Pediatric Prophylactic Vaccines. Also, a 6-year historic analysis is provided for the years 2003-2008. The report also analyzes the global market for Therapeutic Vaccines for the period 2009-2017.
For more details about this comprehensive market research report, please visit –
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/